Dietary supplement use is often not reported to health care teams
the ONA take:
Research from Boston Medical Center found that some clinicians are not asking patients about their dietary supplement use, some patients do not disclose their use of them, and dietary supplement use is often not included in medical documentation.
This can challenge the effectiveness of prescription regimens and lead to serious repercussions for patients.
Researchers recently found an amphetamine-like stimulant in dietary supplements. As a result, stores such as the Vitamin Shoppe pulled as many as 25 supplements off their shelves because they contained the ingredient, which was linked to a woman’s stroke.
Another recent study found a number of supplements may even increase the risk of developing certain cancers.
Patients may not know that their health care team needs this information when planning their care or fear being judged for their use of the products.
The researchers conclude that clinicians need to be more conscious of and better educated on the importance of talking with patients of all ages and cultural backgrounds about dietary supplement use.
Some patients do not disclose their use of them, and dietary supplement use is often not included in medical documentation.
- Neurotoxicity After CAR T-cell Therapy May Be Associated With Endothelial Activation
- Navigation Programs Most Effective in Increasing Follow-up Colonoscopy
- New Class of Clinical Trial Enhances Research on Cancer Care Delivery
- Specialized Interventions Reduce Aberrant Opioid Behaviors in Cancer Patients
- Nivolumab Provides Better Long-Term Efficacy Compared With Docetaxel in NSCLC
- Anticancer Properties of The Probiotic Kefir: A Review
- Navigating the Transition From Treatment to Breast Cancer Survivor
- Combining Radiation, Immunotherapy: An Emerging Challenge for Oncology Nursing
- Naldemedine Effective for Opioid-Induced Constipation in Cancer Pain
- Disruptions to Circadian Rhythm Linked to Prostate Cancer Surgery Regret
- Case Report of a KIT-mutated Melanoma Patient With an Excellent Response to Apatinib and Temozolomide Combination Therapy
- Novel Predictive Model More Effectively Identifies Risk for Lung Cancer
- Long-Term Eltrombopag Increases Platelet Counts, Decreases Bleeding in ITP
- Overall Survival Increase for Melanoma Brain Metastases
- Prophylactic Prochloperazine Ineffective for Opioid-induced Nausea/Vomiting in Cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|